Protein Production and Kinetics at Scale
Protein Production and Kinetics at Scale
Scaling protein production and kinetics by 100x to advance disease biology, AI-driven drug design, and therapy development.
The Challenges of Proteins Study
Current recombinant protein workflows for producing and studying protein kinetics are complex, time-consuming, and expensive. This presents a significant barrier to understanding the causes of diseases, as well as achieving early detection and cure.
SPOC Platform: Protein Nano Factory and High Plex Kinetics
A transformative technology that produces 1000s of full-length folded proteins on a biosensor chip, enabling the evaluation of protein binding kinetics at just 10% of the current cost. This innovative approach is set to revolutionize AI drug design, pre-clinical drug development, vaccines, protein biomarker discovery for precision medicine and diagnostics.
Our Transformative Technology
We are developing a transformative technology that produces thousands of proteins on a biosensor chip, enabling simultaneous real-time biosensing of thousands of protein bindings and interactions at just 10% of the current cost. This groundbreaking approach also promises to revolutionize pre-clinical drug discovery and wet lab testing of AI-designed drug molecules.
Learn About Our Platform
Understanding Our Genetic Blueprint.
The Challenges of Proteins Study
Current recombinant protein workflows for producing and studying protein kinetics are complex, time-consuming, and expensive. This presents a significant barrier to understanding the causes of diseases, as well as achieving early detection and cure.
SPOC Platform: Protein Nano Factory and High Plex Kinetics
A transformative technology that produces 1000s of full-length folded proteins on a biosensor chip, enabling the evaluation of protein binding kinetics at just 10% of the current cost. This innovative approach is set to revolutionize AI drug design, pre-clinical drug development, vaccines, protein biomarker discovery for precision medicine and diagnostics.
Our Transformative Technology
We are developing a transformative technology that produces thousands of proteins on a biosensor chip, enabling simultaneous real-time biosensing of thousands of protein bindings and interactions at just 10% of the current cost. This groundbreaking approach also promises to revolutionize pre-clinical drug discovery and wet lab testing of AI-designed drug molecules.
Learn About Our Platform
Understanding Our Genetic Blueprint.
Scaling protein production and kinetics by 100x to advance disease biology, AI-driven drug design, and therapy development.
Unveiling the secrets of the proteome.
Unveiling the secrets of the proteome.
Fast-Tracking Therapies
Fast-Tracking Therapies
SPOC is designed to generate proteomic interaction data at 100x the scale and depth, compared to current workflows. SPR kinetic screening facilitates resolving drug bindings with micro-molar to pico-molar kinetic affinities, not feasible with phage and yeast display methods. In near future, SPOC MALDI mass spec screening will output million data points in a single assay.
SPOC is designed to generate proteomic interaction data at 100x the scale and depth, compared to current workflows. SPR kinetic screening facilitates resolving drug bindings with micro-molar to pico-molar kinetic affinities, not feasible with phage and yeast display methods. In near future, SPOC MALDI mass spec screening will output million data points in a single assay.
Unlocking the power of AI drug design
Unlocking the power of AI drug design
In silico designed drug molecules require wet lab testing to validate binding to their protein targets, generate objective data to select and develop promising drug candidates. Training data for AI models is limited. Large-scale, deep characterization datasets on drug-protein binding kinetics are needed to enhance AI model accuracies.
In silico designed drug molecules require wet lab testing to validate binding to their protein targets, generate objective data to select and develop promising drug candidates. Training data for AI models is limited. Large-scale, deep characterization datasets on drug-protein binding kinetics are needed to enhance AI model accuracies.
Accelerating development of best-in-class drugs
Accelerating development of best-in-class drugs
High binding affinities are preferred for monoclonal antibody (mAb) drugs (e.g., Keytruda, Humira), while moderate affinities are optimal for CAR-Ts and BiTEs to prevent T cell exhaustion. In contrast, ADC modalities require tailored optimization of kinetic parameters to minimize dose-limiting off-target toxicities.
High binding affinities are preferred for monoclonal antibody (mAb) drugs (e.g., Keytruda, Humira), while moderate affinities are optimal for CAR-Ts and BiTEs to prevent T cell exhaustion. In contrast, ADC modalities require tailored optimization of kinetic parameters to minimize dose-limiting off-target toxicities.
Our vision is to produce and supply protein biosensor chips globally, to democratize proteomics and help resolve the complex proteome.
Our vision is to produce and supply protein biosensor chips globally, to democratize proteomics and help resolve the complex proteome.
For more information on the SPOC platform, get in touch:
Information
Contact Us
Privacy & Conditions
1600 Adams Drive Suite236 Menlo Park, CA 94025
7201 E Henkel Way, Suite 285 Scottsdale, AZ 85255
480-219-9506
info@spoc.bio
All rights reserved © 2024
For more information on the SPOC platform, get in touch:
Information
Contact Us
Privacy & Conditions
1600 Adams Drive Suite236 Menlo Park, CA 94025
7201 E Henkel Way, Suite 285 Scottsdale, AZ 85255
480-219-9506
info@spoc.bio
All rights reserved © 2024
Early Access to the SPOC Platform is now open. See Below for more information.
Early Access to the SPOC Platform is now open. See Below for more information.
SPOC Early Access Program (EAP)
SPOC Early Access Program (EAP)
Our SPOC Early Access Program (EAP) is now open. We are currently taking on limited pilot projects from select customers focused on traditional & AI aided drug discovery and generating proprietary data for AI model training. Please contact us to learn how SPOC can help your product development.
Our SPOC Early Access Program (EAP) is now open. We are currently taking on limited pilot projects from select customers focused on traditional & AI aided drug discovery and generating proprietary data for AI model training. Please contact us to learn how SPOC can help your product development.
I am interested in Early Access
For more information on the SPOC platform, get in touch:
Information
Contact Us
1600 Adams Drive
Suite236
Menlo Park, CA 94025
7201 E Henkel Way
Suite 285
Scottsdale, AZ 85255
480-219-9506
info@spoc.bio